ClinicalTrials.gg
RecruitingNCT07440147Shift2HealthUpdated Nov 16, 2026

Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers

An interventional study of Verum (A) and Placebo (B) in Obesity & Overweight, Circadian Rhythm Disorders and Gut Microbiota Modulation, sponsored by FH Joanneum Gesellschaft mbH. Recruiting at 1 site in Austria. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by FH Joanneum Gesellschaft mbH · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Obesity with a site in Austria — 14 open to participants now, 23 under way, 8 of them phase 3. Obesity · Austria.

Planned enrollment
22nd of 56
200 · median 120
Started
2026
with 3 others
No phase
25 of 70
2 open now
Primary completion
2027-10
later than 11 of 22 live
Registered
66th of 70
by date

Among the 70 studies in Obesity with a site in Austria, this one is the 22nd largest by planned enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 with no phase, reaches primary completion later than 11 of the 22 other live ones, and was the 66th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

14 of the 70 studies in Obesity with a site in Austria are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 21 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Obesity with a site in Austria, or all of them as a file.
02

Study summary

Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.

Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.

Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.

Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.

The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.

These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.

03

Conditions studied

  • Obesity & Overweight
  • Circadian Rhythm Disorders
  • Gut Microbiota Modulation
  • Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health care or industrial shift worker
  • Employed or self-employed working ≥ 24 h/week
  • Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
  • Night shift work duration > 3 years
  • 4 or more night shifts/month

Exclusion criteria

Exclusion Criteria:

  • of 40 kg/m² or higher
  • Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
  • Bariatric surgery
  • Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
  • Diagnosed diabetes type 1 or type 2
  • Uncontrolled thyroid disease (confirmed by abnormal TSH/T4 levels without stable medication for more than 3 months)
  • Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, or cancer)
  • Immunodeficiency syndrome, active or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
  • Regular intake of anticoagulants
  • Known allergy to any inactive or active ingredients in the study products
  • Participation in other clinical intervention trials during the study
  • Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AB Group

    Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months.

    Dietary Supplement: Verum (A) · Dietary Supplement: Placebo (B)

  • Experimental
    BA Group

    Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months.

    Dietary Supplement: Verum (A) · Dietary Supplement: Placebo (B)

Interventions

  • Dietary supplementVerum (A)

    1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10\^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day.

  • Dietary supplementPlacebo (B)

    1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day.

06

What researchers measure

Primary outcomes

  1. Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo

    Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Secondary outcomes

  1. Change in gut microbiom composition between the baseline and endpoint change in the two periods

    Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  2. Change in FABPi between the baseline and endpoint change in the two periods

    Measurement of FABP intestinal (FABPi) in blood (pg/mL)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  3. Change in zonulin between the baseline and endpoint change in the two periods

    Measurement of zonulin in blood (ng/mL)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  4. Change in LPB between the baseline and endpoint change in the two periods

    Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  5. Change in CRP between the baseline and endpoint change in the two periods

    Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  6. Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods

    SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  7. Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods

    Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  8. Change in blood pressure between the baseline and endpoint change in the two periods

    Systolic BP (mmHG) and diastolic BP (mmHG)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  9. Change in melatonin between the baseline and endpoint change in the two periods

    6-sulfatoxymelatonin in urine (µg/L)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  10. Change in BMI between the baseline and endpoint change in the two periods

    Body mass index (BMI)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  11. Change in body composition between the baseline and endpoint change in the two periods

    Bioelectrical Impedance Analysis (BIA)

    Time frame: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

  12. Change in metabolomics at the end of the two periods

    Metabolomic profiles obtained with LC-MS/MS

    Time frame: At the beginning and the end of each intervention period (week 12, week 28)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 21 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 27, 2026
StartActual
Jan 20, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Feb 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: arm descriptions
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07440147
Lead sponsor
FH Joanneum Gesellschaft mbH
Collaborators
Medical University of Vienna, Københavns Universitet, Erasmus Medical Center, University of Vienna
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Jan 20, 2026
Primary completion
Oct 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Miriam Ressler, PhD
Contact
miriam.ressler@fh-joanneum.at
+4331654536677

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion